ClinicalTrials.gg
TerminatedNCT02826681Updated Apr 11, 2025Results posted

Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia

A Phase 2 interventional study of Injectafer® (Ferric Carboxymaltose - FCM) and Placebo (Normal Saline) in Restless Legs Syndrome (RLS), sponsored by American Regent, Inc.. Terminated at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-11.

Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 2, Interventional, and Treatment

Why this study was terminated
Lack of enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 107 studies in Restless Legs Syndrome with a site in United States — 9 open to participants now, 13 under way, none of them phase 3. Restless Legs Syndrome · United States.

Enrollment
36th of 95
70 · median 46
Started
2017
with 1 other
Phase 2
16 of 107
1 open now
Registered
73rd of 107
by date
Lead sponsor
3 of 107
American Regent, Inc.

Among the 107 studies in Restless Legs Syndrome with a site in United States, this one is the 36th largest by enrollment of the 95 interventional ones that give a count, is one of 2 that started in 2017, is one of 16 in phase 2, and was the 73rd registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

9 of the 107 studies in Restless Legs Syndrome with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Restless Legs Syndrome with a site in United States, or all of them as a file.
02

Study summary

Treatment Phase I and II Primary Objective: To evaluate the efficacy and safety of FCM (750 mg dose x 2) for treatment of Restless Legs Syndrome (RLS) in patients with iron-deficiency anemia (IDA).

Long-Term Extension Phase III Primary Objective: To evaluate the duration of effect of prior FCM treatment and to determine the effectiveness of further iron repletion with FCM when RLS symptoms worsen or reoccur.

Read the detailed description

This will be a Phase II, randomized, placebo-controlled study. All subjects who meet the inclusion criteria, with no exclusion criteria, will qualify to enter the Screening Phase. The study will enroll 70 eligible subjects to receive blinded study drug in Treatment Phase I. All eligible subjects will be randomized in a 1:1 ratio to receive a blinded dose of either FCM 750 mg undiluted slow intravenous (IV) push at 100 mg/minute or a Placebo (15 ml of Normal Saline [NS]) IV push at 2 ml/minute on Day 0 and 7.

A subject will be defined at Day 42 as a Responder if the International Restless Legs Syndrome Severity Scale (IRLSS) score is ≤10 or if the IRLSS score is >10 with a Clinical Global Impression-Improvement (CGI-I) score of much or very much improvement and the subject does not request further treatment for RLS. A subject will be defined as a treatment Non-Responder if neither of these criteria are met.

Non-Responders who do not meet the laboratory criteria for additional dosing will be discontinued from the study and treated for RLS as deemed appropriate by the referring physician. Subjects who are Non-Responders at the end of Treatment Phase I and met the necessary laboratory criteria (ferritin \<300 ng/mL and a TSAT \<45%) will consented for enrollment in Treatment Phase II of the study. These subjects will receive the first of two unblinded doses of FCM (undiluted slow IV push 750 mg 100 mg/minute) on Day 0 of Phase II, which will occur within 7 days of the completing Treatment Phase I visit. The subjects will then receive the second dose of FCM (undiluted slow IV push 750 mg 100 mg/minute) on Day 7. All treated subjects will have blood samples taken for hematology, chemistries and iron indices on Day 14. Treatment efficacy (IRLSS score), medication review and adverse events assessment by phone will be done on Day 28. All subjects will return to the clinic on Day 42 for end of study assessments. Subjects completing Treatment Phase II will be re-evaluated on Day 42 and defined as either a Responder or Non-Responder, using the same criteria described above. Subjects deemed as treatment Non-Responders will be discontinued from the study after final assessments are complete.

Subjects who are evaluated on Day 42 (Week 6) as Responders from either Treatment Phase I or Treatment Phase II will continue through into the 46-Week, Long-Term Extension Phase III of the study, and be monitored and assessed by phone for RLS symptoms (IRLSS and Hopkins RLS-Sleep Quality Questionnaire [HRSQ]) and adverse events on (approximately every 9 weeks) Weeks 15, 25, 34, 43 and 52 (final follow-up visit). During Phase III subjects may receive additional unblinded treatments with FCM if at any time the subject reports worsening of RLS symptoms (an increase >4 points on the IRLSS compared to the last evaluation captured for that subject) and laboratory criteria are met (ferritin \<300 ng/mL and a TSAT \<45%). Subjects will receive a single FCM 750 mg undiluted slow IV push at 100 mg/minute. See section 6.6 for dosing and assessment outline. No additional treatment will be allowed after the Week 46. A final face-to-face study visit will occur on Week 52 (approximately 365 days since initial Day 0 Treatment). If a clinic visit is not possible, final evaluation will be completed by phone.

03

Conditions studied

  • Restless Legs Syndrome (RLS)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subject ≥18 years of age who is able to give .
  2. Confirmed diagnosis of RLS based on the Cambridge-Hopkins Diagnostic Questionnaire (CHDQ) and the Hopkins-Hening Telephone Diagnostic Interview (HDTI).
  3. IRLSS score ≥15 plus RLS symptoms for at least 3 months and currently occurring ≥2 nights per week.
  4. Iron-deficiency anemia defined as an \<12 g/dl with a ferritin \<20 ng/mL, or ferritin \<100 when TSAT is \<18%.
  5. Subjects on sleep medication must be on a stable dose for at least 6 months prior screening.
  6. Subjects at risk for pregnancy must have a negative pregnancy test at screening and be practicing an acceptable form of , have had a hysterectomy or tubal ligation, or otherwise be incapable of pregnancy, or have practiced any of the following methods of contraception for at least one month prior to study entry: hormonal contraceptives, spermicide with barrier, intrauterine device, or partner sterility.

Exclusion criteria

Exclusion Criteria:

  1. Disorders that require treatment with the same medications used for RLS include:

    peripheral neuropathy and neurodegenerative disorders (i.e. Parkinson's disease or dementia).

  2. Current (past 4 weeks) use of drugs that may cause or treat RLS, e.g. opioids, calcium channel alpha-2-delta ligands, anti-depressants, dopaminergic agonist or antagonists, or centrally-acting antihistamines.
  3. Any medical conditions to MRI.
  4. Abnormal MRI at baseline that would confound the outcome measures.
  5. Secondary RLS due to neurological conditions or head trauma.
  6. History of hemochromatosis, hemosiderosis, other iron storage disorders or iron metabolism disorders.
  7. Women with uterine bleeding (>200 cc blood loss) during the six months prior to screening.
  8. Liver transaminases ( or ALT) greater than two times the (ULN).
  9. Known positive antigen (HBs Ag), unless positive test can be attributed to receipt of Hepatitis B vaccination in childhood or viral antibody (HCV) with evidence of active hepatitis (i.e., AST/ALT greater than two times the ULN).
  10. Known positive -1 or HIV-2 antibodies (anti-HIV).
  11. Active acute or known chronic infections.
  12. Rheumatoid arthritis with symptoms or signs of active inflammation.
  13. Pregnant and lactating women.
  14. Known reaction to any component of Injectafer® (ferric carboxymaltose).
  15. Previously randomized to Injectafer® (FCM or VIT-45) in a clinical trial.
  16. Previous IV iron treatment for RLS.
  17. Parenteral iron, erythropoiesis stimulating agent use or blood transfusion within six weeks prior to the screening visit.
  18. Planned elective surgery during the study year.
  19. Chronic alcohol or drug abuse within the past six months.
  20. Any other pre-existing laboratory abnormality, medical condition, or disease that, in the opinion of Investigator, may cause the subject to be unsuitable for the study or place the subject at potential risk from being in the study, e.g. a , uncontrolled hypertension, unstable ischemic heart disease, or uncontrolled diabetes mellitus.
  21. Subject is unwilling or has conditions that would prohibit them from complying with the study requirements.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
70 participants (actual)

Study arms

  • Active comparator
    Injectafer

    750 mg undiluted slow IVpush (100 mg/minute) of Injectafer® (Ferric Carboxymaltose - FCM)

    Drug: Injectafer® (Ferric Carboxymaltose - FCM)

  • Placebo comparator
    Normal Saline

    Placebo (15 ml of Normal Saline \[NS\]) IV push at 2 ml/minute on Day 0 and 7.

    Drug: Placebo (Normal Saline)

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment Phase I: IRLSS Score Change

    IRLSS (International Restless Legs Syndrome Severity Scale) score change from baseline to Day 42 with comparison between FCM (Ferric Carboxymaltose) vs. Placebo.

    Time frame: Baseline to Day 42

07

Results

Posted Sep 14, 2022

Participant flow

Participant flow — Overall Study
MilestoneInjectaferNormal Saline
Started3535
Completed1213
Not completed2322

Outcome measures

PrimaryTreatment Phase I: IRLSS Score Change

IRLSS (International Restless Legs Syndrome Severity Scale) score change from baseline to Day 42 with comparison between FCM (Ferric Carboxymaltose) vs. Placebo.

Time frame:
Baseline to Day 42
Reported as:
Count of participants · Participants
Treatment Phase I: IRLSS Score Change
ParticipantsInjectaferNormal Saline
Treatment Phase I: IRLSS Score Change1212

Adverse events

Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Injectafer0/12 (0%)0/12 (0%)0/12 (0%)
Normal Saline0/12 (0%)0/12 (0%)0/12 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)InjectaferNormal SalineTotal
<=18 years000
Between 18 and 65 years121325
>=65 years000
Age, Continuous
Age, Continuous(years)InjectaferNormal SalineTotal
Mean40 ± 11.4644.3 ± 10.3442.3 ± 10.87
Sex: Female, Male
Sex: Female, Male(Participants)InjectaferNormal SalineTotal
Female121325
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)InjectaferNormal SalineTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American7916
White549
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)InjectaferNormal SalineTotal
United States121325
08

Study locations

8 sites
  • Synergy San Diego
    Lemon Grove, California 91945, United States
  • Alliance for Multispeciality Research
    Fort Myers, Florida 33912, United States
  • CNS Healthcare
    Orlando, Florida 32801, United States
  • Johns Hopkins Bayview Medical Center
    Baltimore, Maryland 21224-2780, United States
  • Boston Neuro Research
    South Dartmouth, Massachusetts 02169, United States
  • Neurology Center of Las Vegas
    Las Vegas, Nevada 89128, United States
  • Clinical Trial Network
    Houston, Texas 77074, United States
  • The Polyclinic
    Seattle, Washington 98104, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2017 to primary completion in Sep 2021, 49 months.

Results were first posted in Sep 2022, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2016
First posted
Jul 11, 2016
StartActual
Jul 10, 2017
Primary completionActual
Sep 4, 2021
CompletionActual
Jul 1, 2022
Results first posted
Sep 14, 2022
Last update
Apr 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02826681
Responsible party
Sponsor
First posted
Jul 11, 2016
Start date
Jul 10, 2017
Primary completion
Sep 4, 2021
Completion
Jul 1, 2022
Results posted
Sep 14, 2022
Last update
Apr 11, 2025

Study contacts

Khaled Khechen, MD
study director · American Regent

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion